Curbstone Financial Management Corp increases its equity holding in Pfizer Inc. (NYSE:PFE)


Curbstone Financial Management Corp increased its position in shares of Pfizer Inc. (NYSE: PFEGet a rating) by 0.3% in the first quarter, HoldingsChannel.com reports. The fund held 65,901 shares of the biopharmaceutical company after buying an additional 200 shares during the period. Curbstone Financial Management Corp’s holdings in Pfizer were worth $3,412,000 at the end of the last quarter.

A number of other institutional investors have also recently changed their positions in the stock. Baltimore Washington Financial Advisors Inc. bought a new position in Pfizer stock in Q4 valued at around $290,000. PYA Waltman Capital LLC acquired a new stake in Pfizer stock during Q4 worth approximately $31,000. Econ Financial Services Corp acquired a new stake in Pfizer stock during Q4 worth approximately $31,000. Rinkey Investments acquired a new stake in Pfizer stock during Q4 worth approximately $32,000. Finally, Bivin & Associates Inc. acquired a new equity stake in Pfizer during Q4 worth approximately $37,000. Institutional investors hold 66.50% of the company’s shares.

PFE inventory opened at $50.94 on Thursday. The company has a debt ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. Pfizer Inc. has a 1-year low of $38.82 and a 1-year high of $61.71. The company has a market cap of $285.82 billion, a P/E ratio of 11.68, a price-to-earnings growth ratio of 0.63, and a beta of 0.76. The stock has a 50-day simple moving average of $50.51 and a 200-day simple moving average of $52.19.

Pfizer (NYSE: PFEGet a rating) last released its quarterly results on Tuesday, May 3. The biopharmaceutical company reported EPS of $1.62 for the quarter, missing analyst consensus estimates of $1.66 per ($0.04). The company posted revenue of $25.66 billion in the quarter, compared to $24.73 billion expected by analysts. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The company’s revenue for the quarter increased 76.8% year over year. During the same period a year earlier, the company posted EPS of $0.93. On average, equity research analysts expect Pfizer Inc. to post EPS of 6.61 for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Wednesday, June 29 will receive a dividend of $0.40. This represents a dividend of $1.60 on an annualized basis and a yield of 3.14%. The ex-date of this dividend is Thursday, July 28. Pfizer’s dividend payout ratio is currently 36.70%.

Several research analysts have commented on the company. Wells Fargo & Company cut its price target on Pfizer from $60.00 to $55.00 in a Wednesday, May 4 research report. Barclays set a target price of $52.00 on Pfizer in a report on Monday. JPMorgan Chase & Co. set a target price of $57.00 on Pfizer in a report released Tuesday. StockNews.com upgraded Pfizer from a “buy” rating to a “strong buy” rating in a report on Tuesday, April 19. Finally, Citigroup raised its price target on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a Tuesday, April 5 research note. Nine research analysts gave the stock a hold rating, ten gave the company a buy rating and one gave the company a strong buy rating. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $57.26.

In other Pfizer news, please Jennifer B. Damico sold 4,218 shares in a trade that took place on Tuesday, June 7. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares of the company, valued at approximately $585,250.16. The transaction was disclosed in an SEC filing, available at this link. Also, please Jennifer B. Damico sold 4,000 shares in a trade that took place on Monday, May 16. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the transaction, the senior vice president now directly owns 15,064 shares of the company, valued at approximately $760,732. Disclosure of this sale can be found here. In the past ninety days, insiders have sold 41,126 shares of the company worth $2,075,003. 0.05% of the shares are currently held by insiders of the company.

Pfizer profile (Get a rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers drugs and vaccines in various therapeutic areas, including cardiovascular, metabolic and women’s health under the Premarin Family and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, and oral COVID-19 treatment under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.

Further reading

Want to see which other hedge funds hold PFEs? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFEGet a rating).

Institutional ownership by quarter for Pfizer (NYSE:PFE)



Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.